Location History:
- Breda, NL (2006)
- Frankfurt-am-Main, DE (2010)
Company Filing History:
Years Active: 2006-2010
Title: Mirek Jurzak: Innovator in Cardiovascular Safety and Receptor Cloning
Introduction
Mirek Jurzak is a notable inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of pharmacology, particularly in the areas of cardiovascular safety and receptor cloning. With a total of 2 patents, his work has the potential to impact the development of new therapeutics.
Latest Patents
Jurzak's latest patents include a cardiovascular safety assay and the cloning and expression of a novel 5-HT4 receptor. The cardiovascular safety assay provides assays and kits for screening test compounds for their capability to induce cardiotoxicity in a subject. This invention is based on the interaction of astemizole with the HERG potassium channel, which can predict cardiotoxicity during the development of new agents. The second patent involves an isolated or substantially pure form of a nucleic acid molecule encoding a human 5-HT4 receptor. This invention also includes expression vectors and transgenic cells, tissues, or organisms transfected with the nucleic acid molecule.
Career Highlights
Mirek Jurzak is currently associated with Janssen Pharmaceutica NV, a company known for its innovative pharmaceutical solutions. His work at Janssen has allowed him to focus on groundbreaking research that addresses critical health issues.
Collaborations
Throughout his career, Jurzak has collaborated with esteemed colleagues, including Godelieve Irma Christine Maria Heylen and Cornelus Gerardus Maria Janssen. These collaborations have further enriched his research and contributed to the advancement of his inventions.
Conclusion
Mirek Jurzak's contributions to the fields of cardiovascular safety and receptor cloning exemplify the impact of innovative research in pharmacology. His patents reflect a commitment to improving therapeutic development and patient safety.